Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Tek,
I know very well the process you described.
Just compare it to ...let's say CARA; still in development stage, you go long in july (minimum of last year, as for IPCI). you use leverage and you push it...now you are @14...much bigger gain then the strategy used for IPCI.
to me there is more...just a feeling...like somene trying to push Odidi out...just saying
Samsa, luckily IPCI din't raise 10mln last july, otherwise with would stay around this level for ever . LOL
What Angelo explained I believe is exactly what is holding IPCI in this range.
Perfect clear to me the strategy, still don't understand why should be better to keep a stock in close range and keep on shorting, instead of letting it go (or even push it) and eventually shorting at much higher prices.
I also believe that the one-two (FDA acceptance and two days later partnership) will likely broke this behavious for ever, hopefully causing big losses to those making us wait for so long.
GLTA
I would say algo trade and not retail.
Funny doog, I just saw what you wrote while I was messaging Samsa about Purdue/Collegium
Samsa,
best solution for the RDL - no RDL application would be to have Purdue as a Partner.
I remember having read in this board that Collegium was sued by Purdue when filed for NDA, instead of waiting for possible aprroval. Can we see IPCI not being filed so far as a positive or from a legal point of view there is no difference in the timing ?
As Always FDA is taking the longest possible time to take care of IPCI filings.
By the way, did they forgot about our ANDAs ?
"agreed to temporarily reduce the conversion price for conversions at the option of the holders of Notes (the “Conversion Price”) to $0.32 per share of the Company’s common stock, for a period commencing on January 26, 2017 and ending on February 1, 2017 (the “Reduced Conversion Period”).
The Required Holders also agreed to certain volume limitations on sales of the Company’s common stock thereby during the Reduced Conversion Period. "
From the word "Reduce" : It seems that the floor was likely to be 0.80 (0.05 before R/S), and they likely allowed for lower conversion prices (illegally) and they are now trying to fix it in someway.
They also probably have been caught by surprise from the dramatic price action, as desumable by the limitation on the sell volume of new shares.
Now the floor looks to be 0.32 but it is clear that the company has been scr...ed up big time by some hedge fund.
Amigo, if FDA believes that Rexista it's not enough different from current meds, are they going to reject it?
And since I understood you are of the same advise, why being long IPCI right now?
Following your reasoning Rexista is nothing useful but mostly had almost zero value. Is this what you think?
Ehi WZ,
great to have you back. Last time you posted we were sitting aroung 1.80.
Egalet was around 0.17.
I perfectly remember I advised you to put aside sarcasm and invest at that time in IPCI.
Now your are back.
Hope it will end up the same way, or even much better for IPCI shareholders.
We are well aware of your point of view and we thank you for trying to save us.
GL with your investment, and I'm serious, since I don't like anybody to be hit by losses, it's not a game I win-You lose
Amigo,
sometimes it gets hard for me to have a proper understanding of technical writing at first read.
My question was intended to understand if the company could get a priority review designation while receiveing an accptance on the last day.
I know that probably what I am writing doesn't make any sense for you, and for me either now, beacuse I cleared the meaning of the wording in the procedure, mainly thanks to point 11 of the screenshot that Doog posted.
Sorry guys but english it's not my mother language and while Learning a lot sometimes I get lost.
Thanks everybody for the trying to helping me out
Many thanks !
Amigo,
we can then desume that Rexista is not going to have priority review ?
TIA
Could you please explain me how did you get 100mln shares?
I mean if can show me the calculation made to arrive from first tranche of convertibles to 100mln shares.
TIA
The solution is that kind of partnership Angelo illustrated more than once.
Multiple steps, milestones, as the products gets further in the development/approvals.
An agreement which in the end could reach UP TO....Say 2bln...In 5yrs...And everybody is happy...And we move to Vegas for a year or two..LOL
Not even today we break out resistance...So far
One BIG reason more for Purdue to partner/buy IPCI...
in case everything is not already set-up and done (with whom we will discover soon)
Form Purdue point of view...that's the strategic move the should be making.
Partern for Rexista+Prodras, showing the world they care about addiction and abuse, using their sales channels to even improve their total sales at the end of the story.
Makes sense.
Wrote about it more than once in the past.
We will see, but I would think that would be a game changer for both the companies.
Same for acceptance with the plus that you can sell all shares and live happy....eventually forgetting about IPCI.
to me looks like an error, and they should put out an amendment.
otherwise as you said they made somthing illegal, since after a R/S every doc which include shares counting/price should be applied taking into consideration the R/S ratio
Labeling and Negotiations
Many here wrote about the importance of receivend an Abuse resistant label and I think that this will eventually be the game changer for the company.
1) Is that right to say that currently no competitors already in the market have an Abuse Resistant label ?
Coming to negotiations with potential partners; from the kind of Agreement the made for Focalin I tend to consider that IPCI has good negotatiors and advisers. But maybe what they did with PAR was just standrd practice (I mean the part where if PAR launched its own version then IPCI is still entitled to royalties etc.).
2) What do you think ?
still today, monday or tuesday to have FDA news.
Are possible outcomes just ACCEPTED (with a PDUFA date) or REJECTED ?
is there any other 'grey' answer ?
TIA
And when the h... are we going to hear something about ANDAs....it's becoming tragic and ridicolous at the same time
OK, declaes, thanks for informing me and honestly admitting what heppened.
No prob. Now the next catalyst will likely be qurterly results ?
It seems impossible to understand where this stock will find a floor; the 0.05 conversion minimum ?
I thought it had to be adjusted for the RS (becoming 0.80) but price action seem to point otherwise.
and worst than everything is that there is no clear deadline for this mess to finish; which is the conversion window ?
this is wash trading at its maximum level
Amigo I didn't mean to sound provocative, but looking at your points this is a stock you don't want to know...And maybe is the sad reality.
Hope to see a buyout, this stock is sick
So with the next catalyst we go below 2...Amigo, I respect your analysis and the points you raised seem very reasonable.
But the conclusion after reading them is Sell/short.
Sprot is becoming the king
Just wanted to say reasons maybe more than one...
This stock is a nightmare hopefully becaming the sweetest dream.
Shares outstanding:
as per the last presentation, 29.8Mln as of 30nov2016
as per company presentation in oct, 29Mln as of 31aug2016.
800K new shares in 3months (around 265K per month).
If that pace is still continung we have another reason for the price to go down.
short interest was 1.64M shares as of 31 december; it was 1.06M in July 2016.
So it seems that the really badly timed and structured shares issuance is still hurting us, because the shorts have been steadly increasing (just a small reduction in november) since then.
Now if we consider the floating shares 1.64M is around 6.9% (as per Bloomberg floating shares are currently 23.7Mln); my belief is that the Real floating is likely to be half of that number, putting the short ratio at almost 15%, which is remarkably high.
It appears counter intuitive that while the company was delivering, shorts were increasing.
This is the reason we are not going anywhere: stock is heavely manipulated. By who ? retailers, speculators arbitrageurs (shares vs warrants), brokers under a mandate by competitors or possible bidders (purdue ?)...whatever, that's the way it is.
Only one thing is going to change this situation: a BIG upfront payment (via the Partnership) or TIME to get the revenue and net profit come into the balance sheet, as too many people are valuing IPCI using parameters which are not usually applied to small cap growth companies.
JMHO
GLTA longs.
Samsa,
I'm not sure that the "intent" was then translated into a real sale transaction, couldn't find any confirmation.
But I agree with most here that the amount is not material for any second thoughts.
Let's hope for a magic week with an ANDA approval and FDA acceptance letter.
Few shares driving the price down.
Garden, how can you predict news and their valence, by the chart ?
If no news hit, then chart tend to follow traders action, based on technical analysis.
But news hit a new world starts and this is even more true with biotechs.
Just have a look at HTBX for istance: even looking at it in retrospective you can easily see that from the chart it was impossible to predict future action.
au contraire: at the end of november chart was screaming a very good news was about to hit...but then it was the opposite.
I could give you tens of examples.
Make your DD on this subject
Sprot the stock is manipulated, and you know it.
So don't be surprise to see the price going down while the fundamentals are improving. that's the IPCI's way. it's just disgusting, but never before we have been so close to a company historical reversal.
It's difficult for me not throwing up when looking and share price action, but that is when you BUY instead of when you SELL.
With all the DD made throughout this board you can be quite confident that by the end of the year we will be much higher than today.
But obviously you and Garden have to follow your gut and sell. I can understand you, this stock sucks, but yours it's an emotional sell, badly timed by definition
and WHY no partnership ?
everything can happen but honestly this sounds very unlikely; maybe we get an Agreement wich is someway frustrating, may be we get one hell of a partnership.
but nothing at all ? makes no sense
Thanks delaes, much appreciated.
3mln cash. 15mln shares, it's like 20% of cash per share.
That's the minimum I would like to see reflected in the shares price
out of table I would say.
the conversion structure/repayment is a mess. hope the company is deliberately holding the trails results in order to release them from monday, once this unbelievable orchestrated operation is finished.
ok, thanks, so there will be no change of control, but the diluition will be massive and if the company doesn't come out with important developments on its trials before the next debt installment I think the stock will be disintegrated.
sadly I'm long @ 1.40
mkt cap of 1.2mln is something I wouldn't have expected.
Me as well
Correct to say that if they have to repay the first 3m usd of convertible using new shares, the convertible holder of the first tranche is going to became the major company shareholder from next Monday?
TIA
Samsa, how does it work usually the right of first refusal? thanks
Yes I have read about the 3m on this board. How did u get the info and why aren't they PR it?
Guys what's the meaning of Trump's words against biotech?
TIA